Literature DB >> 9336663

Prospects for the development of fungal vaccines.

G S Deepe1.   

Abstract

In an era that emphasizes the term "cost-effective," vaccines are the ideal solution to preventing disease at a relatively low cost to society. Much of the previous emphasis has been on childhood scourges such as measles, mumps, rubella, poliomyelitis, and Haemophilus influenzae type b. The concept of vaccines for fungal diseases has had less impact because of the perceived limited problem. However, fungal diseases have become increasingly appreciated as serious medical problems that require recognition and aggressive management. The escalation in the incidence and prevalence of infection has prompted a renewed interest in vaccine development. Herein, I discuss the most recent developments in the search for vaccines to combat fungal infections. Investigators have discovered several inert substances from various fungi that can mediate protection in animal models. The next challenge will be to find the suitable mode of delivery for these immunogens.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9336663      PMCID: PMC172935          DOI: 10.1128/CMR.10.4.585

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  103 in total

Review 1.  Antibody immunity and invasive fungal infections.

Authors:  A Casadevall
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

Review 2.  Experimentally induced immunity in the mycoses.

Authors:  Y C Kong; H B Levine
Journal:  Bacteriol Rev       Date:  1967-03

3.  Delayed hypersensitivity to cryptococcin in man.

Authors:  H G Muchmore; F G Felton; S B Salvin; E R Rhoades
Journal:  Sabouraudia       Date:  1968-10

4.  Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection.

Authors:  S C Schimpff; J E Bennett
Journal:  J Allergy Clin Immunol       Date:  1975-06       Impact factor: 10.793

5.  Significance of thymus-derived lymphocytes in immunity elicited by immunization with ribosomes or live yeast cells of Histoplasma capsulatum.

Authors:  R P Tewari; D K Sharma; A Mathur
Journal:  J Infect Dis       Date:  1978-11       Impact factor: 5.226

6.  Mechanisms of resistance to infection with Coccidioides immitis in mice.

Authors:  L V Beaman; D Pappagianis; E Benjamini
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

7.  Protection against mycoplasma infection using expression-library immunization.

Authors:  M A Barry; W C Lai; S A Johnston
Journal:  Nature       Date:  1995-10-19       Impact factor: 49.962

8.  Coccidioides immitis vaccine: potential of an alkali-soluble, water-soluble cell wall antigen.

Authors:  G Lecara; R A Cox; R B Simpson
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

9.  Characterization of antigens from the yeast phase of Histoplasma capsulatum.

Authors:  J P Garcia; D H Howard
Journal:  Infect Immun       Date:  1971-08       Impact factor: 3.441

10.  Treatment of equine phycomycosis by immunotherapy and surgery.

Authors:  R I Miller
Journal:  Aust Vet J       Date:  1981-08       Impact factor: 1.281

View more
  17 in total

1.  Antibody response to Cryptococcus neoformans proteins in rodents and humans.

Authors:  L C Chen; D L Goldman; T L Doering; L a Pirofski; A Casadevall
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Biochemical and immunological characterization of MP65, a major mannoprotein antigen of the opportunistic human pathogen Candida albicans.

Authors:  M J Gomez; B Maras; A Barca; R La Valle; D Barra; A Cassone
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  T-Cell epitopes and human leukocyte antigen restriction elements of an immunodominant antigen of Blastomyces dermatitidis.

Authors:  W L Chang; R G Audet; B D Aizenstein; L H Hogan; R I DeMars; B S Klein
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 4.  [Therapeutic or prophylactic antifungal vaccination: problems and solutions].

Authors:  S Boneberger; H C Korting
Journal:  Hautarzt       Date:  2008-10       Impact factor: 0.751

5.  Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis.

Authors:  Stephen P Saville; Anna L Lazzell; Ashok K Chaturvedi; Carlos Monteagudo; Jose L Lopez-Ribot
Journal:  Clin Vaccine Immunol       Date:  2009-01-14

6.  A 70-kilodalton recombinant heat shock protein of Candida albicans is highly immunogenic and enhances systemic murine candidiasis.

Authors:  C Bromuro; R La Valle; S Sandini; F Urbani; C M Ausiello; L Morelli; C Fé d'Ostiani; L Romani; A Cassone
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

7.  Concentration determination of a recombinant vaccine antigen adsorbed onto an alum adjuvant by chemiluminescent nitrogen detection.

Authors:  John V Amari; Philip Levesque; Zhirui Lian; Trish Lowden; Uditha deAlwis
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

8.  Identification of continuous B-cell epitopes on the protein moiety of the 58-kiloDalton cell wall mannoprotein of Candida albicans belonging to a family of immunodominant fungal antigens.

Authors:  A Viudes; S Perea; J L Lopez-Ribot
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

9.  Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine.

Authors:  Carla Bromuro; Antonella Torosantucci; Paola Chiani; Stefania Conti; Luciano Polonelli; Antonio Cassone
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

10.  Prophylaxis and Therapeutic Ability of Inactivated Dermatophytic Vaccine Against Dermatophytosis in the Rabbits as an Animal Model

Authors:  Ali Abdul Hussein S Al-Janabi; Falah Hasan Obayes Al-Khikani
Journal:  Turk J Pharm Sci       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.